Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2008

View Archived Issues

siRNAs targeting PCSK9 reduce cholesterol in animals

Development of cannabinoid CB1 ligands for brain imaging described

Novel dual HER1/HER2 inhibitor shows antitumor activity in vivo

Novel spirofuran potassium channel openers designed for urinary incontinence

Novel alpha7 neuronal nicotinic receptor agonists synthesized at Abbott

New agents for treating obesity and nutritional disorders presented in recent patents

GPR88 identified as a potential target in psychiatric disorders

Novel JAK-3 inhibitor active as immunosuppressant in trachea transplanted rats

Clinical benefits and safety of novel antiplatelet agent SCH-530348 disclosed at the ESC congress

GSK withdraws European MAA for Quintanrix vaccine

FDA notifies Introgen that Advexin BLA not sufficiently complete to file

FDA accepts Alpharma's Embeda capsule NDA filing

GlaxoSmithKline returns Entereg rights to Adolor for opioid bowel dysfunction

Recent Vertex patent discloses new agents for AD and other neurological disorders

Idera receives milestone payment under asthma and allergy collaboration

Recent Boehringer Ingelheim patent describes novel analgesic agents

Olanzapine long-acting injection maintains treatment benefit for up to six months

Targanta presents top-line results from oritavancin phase II SIMPLIFI trial

Roche pays USD 15 million milestone to InterMune for development of HCV protease inhibitor

Pain Therapeutics receives USD 20,000,000 in milestone payments from King Pharmaceuticals

Vimpat approved in the E.U. for partial-onset seizures

HGS reports initial top-line results from phase II HGS-ETR1 trial

Intercell reports favorable six months follow-up results from phase II HCV trial